1
|
Inaba H and Mullighan CG: Pediatric acute
lymphoblastic leukemia. Haematologica. 105:2524–2539. 2020.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Shallis RM, Wang R, Davidoff A, Ma X and
Zeidan AM: Epidemiology of acute myeloid leukemia: Recent progress
and enduring challenges. Blood Rev. 36:70–87. 2019. View Article : Google Scholar : PubMed/NCBI
|
3
|
Stengel A, Kern W, Haferlach T,
Meggendorfer M, Fasan A and Haferlach C: The impact of TP53
mutations and TP53 deletions on survival varies between AML, ALL,
MDS and CLL: An analysis of 3307 cases. Leukemia. 31:705–711. 2017.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Stengel A, Schnittger S, Weissmann S,
Kuznia S, Kern W, Kohlmann A, Haferlach T and Haferlach C: TP53
mutations occur in 15.7% of ALL and are associated with
MYC-rearrangement, low hypodiploidy, and a poor prognosis. Blood.
124:251–258. 2014. View Article : Google Scholar : PubMed/NCBI
|
5
|
Kantidze OL, Luzhin AV, Nizovtseva EV,
Safina A, Valieva ME, Golov AK, Velichko AK, Lyubitelev AV,
Feofanov AV, Gurova KV, et al: The anti-cancer drugs curaxins
target spatial genome organization. Nat Commun. 10:14412019.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Dallavalle S, Mattio LM, Artali R, Musso
L, Aviñó A, Fàbrega C, Eritja R, Gargallo R and Mazzini S:
Exploring the interaction of curaxin CBL0137 with G-quadruplex DNA
oligomers. Int J Mol Sci. 22:64762021. View Article : Google Scholar : PubMed/NCBI
|
7
|
Gasparian AV, Burkhart CA, Purmal AA,
Brodsky L, Pal M, Saranadasa M, Bosykh DA, Commane M, Guryanova OA,
Pal S, et al: Curaxins: Anticancer compounds that simultaneously
suppress NF-κB and activate p53 by targeting FACT. Sci Transl Med.
3:95ra742011. View Article : Google Scholar : PubMed/NCBI
|
8
|
Lock R, Carol H, Maris JM, Kolb EA,
Gorlick R, Reynolds CP, Kang MH, Keir ST, Wu J, Purmal A, et al:
Initial testing (stage 1) of the curaxin CBL0137 by the pediatric
preclinical testing program. Pediatr Blood Cancer. 64:e262632017.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Somers K, Kosciolek A, Bongers A,
El-Ayoubi A, Karsa M, Mayoh C, Wadham C, Middlemiss S, Neznanov N,
Kees UR, et al: Potent antileukemic activity of curaxin CBL0137
against MLL-rearranged leukemia. Int J Cancer. 146:1902–1916. 2020.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Forgione MO, McClure BJ, Eadie LN, Yeung
DT and White DL: KMT2A rearranged acute lymphoblastic leukaemia:
Unravelling the genomic complexity and heterogeneity of this
high-risk disease. Cancer Lett. 469:410–418. 2020. View Article : Google Scholar : PubMed/NCBI
|
11
|
Muntean AG and Hess JL: The pathogenesis
of mixed-lineage leukemia. Annu Rev Pathol. 7:283–301. 2012.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Marks DI, Moorman AV, Chilton L, Paietta
E, Enshaie A, DeWald G, Harrison CJ, Fielding AK, Foroni L,
Goldstone AH, et al: The clinical characteristics, therapy and
outcome of 85 adults with acute lymphoblastic leukemia and
t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the
UKALLXII/ECOG2993 trial. Haematologica. 98:945–952. 2013.
View Article : Google Scholar : PubMed/NCBI
|
13
|
Aubrey BJ, Kelly GL, Kueh AJ, Brennan MS,
O'Connor L, Milla L, Wilcox S, Tai L, Strasser A and Herold MJ: An
inducible lentiviral guide RNA platform enables the identification
of tumor-essential genes and tumor-promoting mutations in vivo.
Cell Rep. 10:1422–1432. 2015. View Article : Google Scholar : PubMed/NCBI
|
14
|
Ralph P, Moore M and Nilsson K: Lysozyme
synthesis by established human and murine histiocytic lymphoma cell
lines. J Exp Med. 143:1528–1533. 1976. View Article : Google Scholar : PubMed/NCBI
|
15
|
Chanput W, Peters V and Wichers H: THP-1
and U937 cells. The Impact of Food Bioactives on Health. Verhoeckx
K, Cotter P, López-Expósito I, Kleiveland C, Lea T, Mackie A,
Requena T, Swiatecka D and Wichers H: Springer; Cham: pp. 147–159.
2015
|
16
|
Barretina J, Caponigro G, Stransky N,
Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV,
Sonkin D, et al: The cancer cell line encyclopedia enables
predictive modelling of anticancer drug sensitivity. Nature.
483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
|
17
|
Tate JG, Bamford S, Jubb HC, Sondka Z,
Beare DM, Bindal N, Boutselakis H, Cole CG, Creatore C, Dawson E,
et al: COSMIC: The catalogue of somatic mutations in cancer.
Nucleic Acids Res. 47(D1): D941–D947. 2019. View Article : Google Scholar : PubMed/NCBI
|
18
|
Landrum MJ, Lee JM, Benson M, Brown GR,
Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al:
ClinVar: Improving access to variant interpretations and supporting
evidence. Nucleic Acids Res. 46(D1): D1062–D1067. 2018. View Article : Google Scholar : PubMed/NCBI
|
19
|
Zhang JD, Ruschhaupt M and Biczok R: ddCt
method for qRT-PCR data analysis. Bioconductor. 2013.http://www.bioconductor.org/packages/release/bioc/vignettes/ddCt/inst/doc/rtPCR.pdfOctober
26–2021
|
20
|
He G, Siddik ZH, Huang Z, Wang R, Koomen
J, Kobayashi R, Khokhar AR and Kuang J: Induction of p21 by p53
following DNA damage inhibits both Cdk4 and Cdk2 activities.
Oncogene. 24:2929–2943. 2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
Xia M, Knezevic D and Vassilev LT: p21
does not protect cancer cells from apoptosis induced by
nongenotoxic p53 activation. Oncogene. 30:346–355. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Sarantopoulos J, Mahalingam D, Sharma N,
Iyer RV, Ma WW, Ahluwalia MS, Johnson S, Purmal A, Shpigotskaya P,
Hards A, et al: Results of a completed phase I trial of CBL0137
administered intravenously (IV) to patients (Pts) with advanced
solid tumors. J Clin Oncol. 38 (Suppl 15):S35832020. View Article : Google Scholar
|
23
|
Fedyanin M, Tryakin A, Lisyanskaya AS,
Solovyeva E, Fadeeva N, Gladkov O, Moiseyenko V, Cheporov SV,
Shpigotskaya P, Purmal A, et al: Results of a completed
first-in-human phase Ib dose-escalation study of oral CBL0137 in
patients with advanced solid tumors. J Clin Oncol. 38 (Suppl
15):S36072020. View Article : Google Scholar
|
24
|
Chua MMJ, Lee M and Dominguez I:
Cancer-type dependent expression of CK2 transcripts. PLoS One.
12:e01888542017. View Article : Google Scholar : PubMed/NCBI
|